Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Gains from Investment Securities (2020 - 2023)

Historic Gains from Investment Securities for Cullinan Therapeutics (CGEM) over the last 4 years, with Q4 2023 value amounting to -$9.1 million.

  • Cullinan Therapeutics' Gains from Investment Securities fell 27514.85% to -$9.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$4.4 million, marking a year-over-year decrease of 11172.72%. This contributed to the annual value of $10.4 million for FY2024, which is 33460.41% up from last year.
  • Cullinan Therapeutics' Gains from Investment Securities amounted to -$9.1 million in Q4 2023, which was down 27514.85% from $4.6 million recorded in Q2 2023.
  • Cullinan Therapeutics' 5-year Gains from Investment Securities high stood at $32.7 million for Q3 2022, and its period low was -$9.1 million during Q4 2023.
  • In the last 4 years, Cullinan Therapeutics' Gains from Investment Securities had a median value of $4.6 million in 2020 and averaged $5.2 million.
  • Data for Cullinan Therapeutics' Gains from Investment Securities shows a peak YoY increase of 363664.12% (in 2023) and a maximum YoY decrease of 27514.85% (in 2023) over the last 5 years.
  • Over the past 4 years, Cullinan Therapeutics' Gains from Investment Securities (Quarter) stood at $4.6 million in 2020, then skyrocketed by 131.79% to $10.7 million in 2021, then tumbled by 51.22% to $5.2 million in 2022, then plummeted by 275.15% to -$9.1 million in 2023.
  • Its Gains from Investment Securities stands at -$9.1 million for Q4 2023, versus $4.6 million for Q2 2023 and $75000.0 for Q1 2023.